BioTime Enters into Worldwide License Agreement with UCLA to Develop Therapy for the Treatment of Stroke ALAMEDA, Calif.--(BUSINESS WIRE)

Enters into Worldwide License Agreement with UCLA to Develop Therapy for

the Treatment of Stroke

ALAMEDA, Calif.--(BUSINESS WIRE)--April 19, 2013--BioTime, Inc. (NYSE

MKT: BTX) today announced that it has entered into an exclusive license

agreement with the University of California, Los Angeles (UCLA) for

novel technology related to the treatment of stroke. The licensed

technology, developed in the laboratories of Tom Carmichael, MD, PhD of

UCLA's Department of Neurology, at the David Geffen School of Medicine,

uses one of BioTime's HyStem hydrogels to

deliver locally released growth factors to improve recovery from stroke.

Pre-clinical studies have demonstrated that the localized delivery of

growth factors such as brain-derived neurotrophic factor (BDNF) results

in a statistically significant improvement in post-stroke motor function

in a murine model of ischemic stroke.

Concurrent with the execution of this exclusive license agreement,

BioTime has entered into a Sponsored Research Agreement with UCLA to

support on-going pre-clinical work in Dr. Carmichael's laboratory to

advance the understanding of this technology and develop data in support

for the potential filing of an Investigational New Drug Application

(IND) for human clinical trails.

BioTime, headquartered in Alameda, California, is a biotechnology

company focused on regenerative medicine and blood plasma volume

expanders. Its broad platform of stem cell technologies is enhanced

through subsidiaries focused on specific fields of application. BioTime

develops and markets research products in the fields of stem cells and

regenerative medicine, including a wide array of proprietary PureStem

cell lines, HyStem hydrogels, culture media, and

differentiation kits. BioTime is developing Renevia (formerly

known as HyStem -Rx), a biocompatible,

implantable hyaluronan and collagen-based matrix for cell delivery in

human clinical applications. BioTime's therapeutic product development

strategy is pursued through subsidiaries that focus on specific organ

systems and related diseases for which there is a high unmet medical

need. BioTime's majority-owned subsidiary Cell Cure Neurosciences Ltd.

is developing therapeutic products derived from stem cells for the

treatment of retinal and neural degenerative diseases. BioTime's

subsidiary OrthoCyte Corporation is developing therapeutic applications

of stem cells to treat orthopedic diseases and injuries. Another

subsidiary, OncoCyte Corporation, focuses on the diagnostic and

therapeutic applications of stem cell technology in cancer, including

the diagnostic product PanC-Dx currently being developed for the

detection of cancer in blood samples. ReCyte Therapeutics, Inc. is

developing applications of BioTime's proprietary induced pluripotent

stem cell technology to reverse the developmental aging of human cells

to treat cardiovascular and blood cell diseases. BioTime's subsidiary

LifeMap Sciences, Inc. markets GeneCards , the

leading human gene database, as part of an integrated database suite

that also includes the LifeMap Discovery database of embryonic

development, stem cell research and regenerative medicine, and MalaCards,

the human disease database. LifeMap Sciences also markets BioTime

research products and PanDaTox, an innovative, recently

developed, searchable database that can aid in the discovery of new

antibiotics and biotechnologically beneficial products. Asterias

Biotherapeutics, Inc. is a new subsidiary being used to acquire the stem

cell assets of Geron Corporation, including patents and other

intellectual property, biological materials, reagents, and equipment for

the development of new therapeutic products for regenerative medicine.

BioTime's lead product, Hextend , is a blood

plasma volume expander manufactured and distributed in the U.S. by

Hospira, Inc. and in South Korea by CJ CheilJedang Corporation under

exclusive licensing agreements. Additional information about BioTime can

be obtained at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results,

future growth in research, technology, clinical development, and

potential opportunities for BioTime and its subsidiaries, along with

other statements about the future expectations, beliefs, goals, plans,

or prospects expressed by management constitute forward-looking

statements. Any statements that are not historical fact (including, but

not limited to statements that contain words such as "will," "believes,"

"plans," "anticipates," "expects," "estimates") should also be

considered to be forward-looking statements. Forward-looking statements

involve risks and uncertainties, including, without limitation, risks

inherent in the development and/or commercialization of potential

products, uncertainty in the results of clinical trials or regulatory

approvals, need and ability to obtain future capital, and maintenance of

intellectual property rights. Actual results may differ materially from

the results anticipated in these forward-looking statements and as such

should be evaluated together with the many uncertainties that affect the

business of BioTime and its subsidiaries, particularly those mentioned

in the cautionary statements found in BioTime's Securities and Exchange

Commission filings. BioTime disclaims any intent or obligation to update

these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the

following link to join our email alert list:

Chief Financial Officer